High-dose Tamoxifen may prolong survival in amyotrophic lateral sclerosis (ALS)

Neurologist Benjamin Brooks, who directs the MDA ALS Center at the University of Wisconsin-Madison, presented results of a trial of tamoxifen, a drug approved for the treatment of breast cancer, at a meeting of the American Academy of Neurology in April. The trial was supported in part by MDA.

In a two-year study of 60 people with amyotrophic lateral sclerosis (ALS) who took varying dosages of tamoxifen, which changes the way the body responds to the female hormone estrogen, Brooks found that participants who took more than 20 milligrams a day had a better survival rate than those who took fewer than 10 milligrams a day.

After two years, 27 out of 37 (73 percent) of the participants in the high-dose tamoxifen group had survived, while only 11 of 23 (48 percent) of those in the low-dose groups were still living.

There was no difference among the various dosage groups on measures of muscle strength, respiratory capacity, activities of daily living or functional abilities.

Brooks cautioned that a longer trial would be necessary to demonstrate with certainty that there’s a survival benefit to taking tamoxifen at the higher doses.

He’s planning further studies to investigate the effects of tamoxifen and also recommends that the metabolic products of tamoxifen be studied.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study could lead to a more potent treatment option for multiple sclerosis